Core Viewpoint - The report from CICC indicates an upward revision of the 2025 adjusted net profit forecast for Jinxin Fertility (01951) by 19% to 200 million yuan, while the 2026 forecast is lowered by 34% to 280 million yuan due to increased costs and changes in financial confirmation methods [1] Group 1: Financial Performance - The expected adjusted net profit for FY 2025 is approximately 200 million yuan, with a slight year-on-year decline in revenue, but a noticeable improvement in the second half of 2025 [1] - The company anticipates a recovery in the number of cycles starting from the second half of 2025, with a projected return to stable growth in 2026, expecting a growth rate of 5-10% in cycles and revenue [1][2] Group 2: Operational Improvements - The company has completed the handling of overseas asset impairment and other risk issues in the first half of 2025, with a significant improvement expected in the second half [2] - The company is focusing on core business operations, aiming to enhance market share and improve cash flow, with plans for a long-term stock buyback after reducing leverage [2]

Core Viewpoint - The company Jin Xin Reproductive (01951) is expected to see a recovery in its business in the second half of 2025, leading to a 19% increase in the adjusted net profit forecast for 2025 to 200 million yuan. However, the forecast for 2026 has been reduced by 34% to 280 million yuan due to increased costs and changes in financial confirmation methods, with a new forecast for 2027 set at 360 million yuan. The current stock price corresponds to a 24.8 times P/E ratio for 2026, and the target price has been lowered by 10% to 3.5 HKD, indicating a potential upside of 41.1% from the current level [1]. Group 1 - The adjusted net profit for fiscal year 2025 is projected to be approximately 200 million yuan, with a slight year-on-year decline in revenue expected [2]. - The company is anticipated to release its full-year results for 2025 in late March, with significant quarter-on-quarter improvements expected in the second half of 2025 [2]. Group 2 - The company is expected to see a gradual improvement in cycle numbers starting from the second half of 2025, with a return to stable growth in 2026, driven by the inclusion of assisted reproduction in health insurance policies [3]. - The overall cycle count for fiscal year 2025 is projected to decline by 1.4% year-on-year, a significant improvement compared to earlier periods [3]. Group 3 - The company has completed the handling of overseas asset impairment and other risk issues in the first half of 2025, with a notable improvement in the second half of the year [4]. - The adjusted net profit for fiscal year 2025 is expected to be around 200 million yuan, with EBITDA for 2026 projected to return to approximately 550 million yuan, indicating improvements in net profit and free cash flow [4]. Group 4 - The company is focusing on its core business and plans to enhance shareholder returns, with the new Shenzhen hospital expected to be fully operational by the first quarter of 2026 [5]. - The company is actively pursuing a restructuring of its U.S. HRC operations, with significant improvements and capital recovery expected by the end of the first half of 2026 [5].

Core Viewpoint - The company is expected to report a slight decline in revenue for FY25, with an adjusted net profit of approximately 200 million yuan, but a noticeable improvement in both revenue and profit is anticipated in the second half of FY25 [1][2]. Group 1: Revenue and Profit Forecast - For FY25, the company anticipates a year-on-year decline in revenue, with a cumulative cycle count down by 1.4% compared to previous periods, but this is an improvement from declines of 8.3% and 5.2% in the first half of FY25 and the first three quarters of FY25, respectively [1]. - The company expects a recovery in cycle counts and revenue growth of 5-10% in FY26, driven by the inclusion of assisted reproduction in health insurance policies, which is expected to increase the proportion of artificial insemination (IUI) cycles [1]. Group 2: Operational Quality and Asset Structure - The company has completed the handling of overseas asset impairment and other risk issues in the first half of FY25, leading to a forecasted adjusted net profit of approximately 200 million yuan for FY25, with significant improvements expected in the second half [2]. - Continuous efforts in structural optimization, cost management, and asset quality improvement are expected to yield positive results in FY26, with an EBITDA forecast of around 550 million yuan, alongside improvements in net profit and free cash flow [2]. Group 3: Strategic Focus and Shareholder Returns - The company plans to complete the relocation of its new Shenzhen hospital by the first quarter of FY26, aiming to enhance its market share in core business areas [2]. - The company is actively pursuing a restructuring of its U.S. HRC operations, with significant improvements and capital recovery expected by the end of the first half of FY26, and plans to initiate a long-term stock repurchase program after reducing leverage [2]. Group 4: Earnings Forecast and Valuation - The adjusted net profit forecast for FY25 has been raised by 19% to 200 million yuan due to business recovery in the second half, while the FY26 forecast has been lowered by 34% to 280 million yuan, with a new forecast for FY27 set at 360 million yuan [2]. - The current stock price corresponds to a P/E ratio of 24.8 times for FY26 based on adjusted net profit, with a target price adjustment of 10% down to 3.5 HKD, reflecting a potential upside of 41.1% [2].

Group 1 - The stock price of Jinxin Reproductive Medicine (01951) increased by 1.99% to HKD 2.56, with a trading volume of HKD 66.02 million [2][5] - The National Medical Security Work Conference held on December 13 emphasized the need to adapt to population development strategies and promote the development of maternity insurance and long-term care insurance [2][5] - By 2025, all 31 provinces and regions, including Xinjiang Production and Construction Corps, are expected to include eligible assisted reproductive projects in medical insurance, with 7 provinces achieving full coverage of hospitalization costs for childbirth [2][5] Group 2 - Jinxin Reproductive Medicine announced a share buyback plan with a total price of no less than HKD 100 million, having repurchased 23.224 million shares for HKD 57.717 million last week [2][5] - As of now, the company has completed the buyback of 30.946 million shares this month, totaling HKD 77.515 million [2][5] - The company aims to focus on improving operational performance and enhancing intrinsic value to create sustainable returns for shareholders [2][5]

Core Viewpoint - The stock of Jinxin Fertility (01951) has increased by over 3%, currently trading at 2.6 HKD with a transaction volume of 45.4 million HKD, following the announcement of supportive policies for reproductive health insurance in China [1] Group 1: Industry Developments - The National Medical Security Work Conference held on December 13 in Beijing emphasized the need to adapt to population development strategies and promote the growth of maternity insurance and long-term care insurance [1] - The conference aims for nationwide basic realization of "no out-of-pocket" expenses for childbirth within the policy scope, with a target for 2025 that all 31 provinces (regions, municipalities) and the Xinjiang Production and Construction Corps will include eligible assisted reproductive projects in medical insurance [1] - Seven provinces are expected to achieve full coverage of hospitalization expenses for childbirth within the policy scope, and 95% of coordinated areas will directly distribute maternity allowances to insured individuals [1] Group 2: Company Actions - Jinxin Fertility announced a decision by its board to utilize buyback authorization to repurchase shares in the open market for a total price of no less than 100 million HKD [1] - Last week, the company repurchased 23.2 million shares at a cost of 57.7 million HKD, and as of now, it has completed the buyback of 30.9 million shares this month, totaling 77.5 million HKD [1] - The company stated its commitment to focus on improving operational performance and driving intrinsic value growth to create sustainable returns for shareholders [1]